The table below shows REGENERON PHARMACEUTICALS, INC.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
$1.08B
$1.05B
$1.51B
$1.37B
$2.10B
$668.50M
Capital expenditure
-
-
-
-
-
-
Investing cash flow
-$428.90M
$647.50M
-$1.69B
-$235.70M
-$1.71B
-$1.06B
Dividends paid
$97.80M
$93.80M
$0.00
-
-
REGN operating cash flow (10-K history)
REGENERON PHARMACEUTICALS, INC. reported operating cash flow of $4.98B for fiscal year 2025. That is up 12.6% from $4.42B in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from $1.49B (FY 2016) to $4.98B. Figures come from the company's audited annual reports as filed with the SEC.
